경카테터 폐동맥판 시장 : 기술별, 원자재별, 용도별, 최종사용자별, 지역별(2025-2033년)

The global transcatheter pulmonary valve market size reached USD 95.5 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 191.7 Million by 2033, exhibiting a growth rate (CAGR) of 7.65% during 2025-2033. The increasing incidence of various cardiovascular diseases (CVDs), extensive research and development (R&D) activities, and the rising geriatric population represent some of the key factors driving the market.

A transcatheter pulmonary valve refers to an artificial valve made from cow, pig, or human heart tissue. It is widely used to replace leaky or narrowed pulmonary valves to improve blood flow, with fewer incisions and faster recovery than open surgery. These valves are inserted through a thin, flexible tube (catheter) into a large blood vessel involving a minimally invasive (MI) procedure. Transcatheter pulmonary valve replacement involves less pain and a shorter recovery period and helps in improving symptoms while lowering the risk of medical complications. It also helps to restore blood flow and reduce the signs and symptoms of aortic valve stenosis, such as chest pain, shortness of breath, fainting, and fatigue. As a result, these valves find extensive applications in cardiac anomaly, pulmonary regurgitation, atresia, stenosis, and truncus arteriosus.

Transcatheter Pulmonary Valve Market Trends:

The rising incidences of various cardiovascular diseases (CVDs), such as rheumatic heart disorders, hypertensive heart diseases, cerebrovascular diseases, and inflammatory heart diseases across the globe, are among the key factors driving the market growth. In line with this, the rising geriatric population and increasing prevalence of degenerative abnormalities associated with severe aortic stenosis and mitral and tricuspid regurgitation are favoring the market growth. Moreover, the widespread product adoption in the treatment of pediatric transcatheter pulmonary is contributing to the market growth. This can be primarily attributed to the increasing frequency of pulmonary stenosis, atresia, tetralogy of Fallot, and other related disorders, which is facilitating the product adoption as an effective treatment option. Apart from this, the integration of artificial intelligence (AI) in the transcatheter pulmonary valve replacement (TPVR) procedure, as it assists in pre-procedural planning, identifying risk factors, and enhancing diagnosis and clinical decision-making, is providing an impetus to the market growth. Additionally, the increasing demand for balloon-expanded technology as it involves a faster and simpler process and offers high accuracy and precision of the result is positively influencing the market growth. Besides this, the launch of the hydra aortic valve, which is a self-expanding supra-annular aortic system made of nitinol that allows precise placement of the valve and ensures orthotopic deployment, is propelling the market growth. Other factors, including growing demand for innovative heart valves, an increasing number of hypertension cases, escalating growth in the healthcare industry, rising expenditure capacities of consumers, extensive research and development (R&D) activities, and the implementation of various government initiatives to develop efficient transcatheter pulmonary valves, are anticipated to create a positive outlook for the market.

Key Market Segmentation:

Technology Insights:

• Balloon-Expanded Transcatheter Valve
• Self-Expanded Transcatheter Valve

Raw Material Insights:

• Tissue Engineered
• Synthetic

Application Insights:

• Tetralogy of Fallot
• Cardiac Anomaly
• Pulmonary Atresia
• Pulmonary Stenosis
• Pulmonary Regurgitation
• Truncus Arteriosus
• Others

End User Insights:

• Adult
• Pediatric

Regional Insights:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others);Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for transcatheter pulmonary valve. Some of the factors driving the North America transcatheter pulmonary valve market included the rising geriatric population, growing demand for innovative heart valves, and various technological advancements.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global transcatheter pulmonary valve market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Artivion Inc., Boston Scientific Corporation, Braile Biomedica, Colibri Heart Valve LLC, Edwards Lifesciences Corporation, JenaValve Technology Inc., Labcor Laboratorios Ltda., Medtronic plc, Venus Medtech (Hangzhou) Inc., etc.

Key Questions Answered in This Report:

• How has the global transcatheter pulmonary valve market performed so far and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global transcatheter pulmonary valve market?
• What are the key regional markets?
• Which countries represent the most attractive transcatheter pulmonary valve markets?
• What is the breakup of the market based on technology?
• What is the breakup of the market based on the raw material?
• What is the breakup of the market based on the application?
• What is the breakup of the market based on the end user?
• What is the competitive structure of the global transcatheter pulmonary valve market?
• Who are the key players/companies in the global transcatheter pulmonary valve market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Transcatheter Pulmonary Valve Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Technology

• 6.1 Balloon-Expanded Transcatheter Valve
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Self-Expanded Transcatheter Valve
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Raw Material

• 7.1 Tissue Engineered
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Synthetic
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Application

• 8.1 Tetralogy of Fallot
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Cardiac Anomaly
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Pulmonary Atresia
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Pulmonary Stenosis
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Pulmonary Regurgitation
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Truncus Arteriosus
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by End User

• 9.1 Adult
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Pediatric
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

• 11.1 Overview
• 11.2 Drivers
• 11.3 Restraints
• 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Artivion Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Boston Scientific Corporation
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Braile Biomedica
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Colibri Heart Valve LLC
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Edwards Lifesciences Corporation
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 JenaValve Technology Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Labcor Laboratorios Ltda.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
  • 15.3.9 Medtronic plc
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Venus Medtech (Hangzhou) Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.